Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Chelsey Yang"'
Autor:
Sharomi Oluwaseun, Chelsey Yang, Su Jian Si Tu, Jia Yin, Yan Song, Qiang Sun, Nabi Kanibir, Susanne Hartwig, Cristina Carias
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024)
Rotavirus (RV) vaccines have demonstrated substantial effectiveness in reducing the healthcare burden caused by gastroenteritis (RVGE) worldwide. This study aims to understand the differential impact of RV vaccination in reducing RVGE burden in child
Externí odkaz:
https://doaj.org/article/44651e6670f14aea97d00bfb74f35483
Autor:
Min Huang, Peter A. Fasching, Amin Haiderali, Weiguang Xue, Chelsey Yang, Wilbur Pan, Zheng-Yi Zhou, Peter Hu, Mitashri Chaudhuri, Celine Le Bailly De Tilleghem, Nicolas Cappoen, Joyce O’Shaughnessy
Publikováno v:
Advances in Therapy. 40:1153-1170
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a3ef10038bd4943075dba2d66d110cdc
https://doi.org/10.1007/s12325-022-02365-1
https://doi.org/10.1007/s12325-022-02365-1
Autor:
Chelsey Yang
Publikováno v:
Nursing ethics. 27(6)
In the medical field, conscientious objection is claimed by providers and pharmacists in an attempt to forgo administering select forms of sexual and reproductive healthcare services because they state it goes against their moral integrity. Such clai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73a3d8371cc3556f2164009688042ade
https://pubmed.ncbi.nlm.nih.gov/32400261
https://pubmed.ncbi.nlm.nih.gov/32400261
Autor:
James Signorovitch, Eric Jonasch, William M. Reichmann, Nanxin Li, Zhimei Liu, Nicholas J. Vogelzang, Chelsey Yang, Sumanta K. Pal, Jose Ricardo Perez
Publikováno v:
Current Medical Research and Opinion. 32:741-747
Background Second targeted therapies for metastatic renal cell carcinoma (mRCC) include mammalian target of rapamycin inhibitors (mTORis) and tyrosine kinase inhibitors (TKIs). This observational study compares overall survival (OS) and progression-f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bcac4baa7fbc9a5a5e6b7c35b955e86e
https://doi.org/10.1185/03007995.2016.1140028
https://doi.org/10.1185/03007995.2016.1140028
Autor:
Jinlin Song, Dimitrios P. Kontoyiannis, Hongbo Yang, Sneha S. Kelkar, Nkechi Azie, Chelsey Yang, Alan Fan, James Spalding, Edward I. Lee
Publikováno v:
Open Forum Infectious Diseases. 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::42b7b3e89d0cbc8222ce048b003f3987
https://doi.org/10.1093/ofid/ofv133.334
https://doi.org/10.1093/ofid/ofv133.334
Autor:
Hongbo Yang, Jinlin Song, Chelsey Yang, Sneha Kelkar, Edward Lee, Alan Fan, Nkechi Azie, James Spalding, Dimitrios Kontoyiannis
Publikováno v:
Open Forum Infectious Diseases. 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d7ebb18ecb4c3fce701e63b33d2daf2a
https://doi.org/10.1093/ofid/ofv133.335
https://doi.org/10.1093/ofid/ofv133.335
Autor:
Chelsey Yang, Paul Cockrum, Kejal Parikh, Jipan Xie, Amit Agarwal, Christina Chen, Adina Farrukh, Safiya Abouzaid
Publikováno v:
Journal of Clinical Oncology. 35:e19509-e19509
e19509 Background: Lenalidomide maintenance therapy after autologous stem cell transplant (ASCT) in the first-line treatment has been shown to improve progression-free survival (PFS) and overall survival (OS) in multiple myeloma (MM) patients (pts).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::436018dffbcd1353fc5971914d2e4d42
https://doi.org/10.1200/jco.2017.35.15_suppl.e19509
https://doi.org/10.1200/jco.2017.35.15_suppl.e19509
Publikováno v:
Blood. 126:2090-2090
Background: Nilotinib and dasatinib are common second-line therapy for patients with Ph+ CML-CP who are resistant or intolerant to imatinib. Since their approval, several CEAs comparing second-line nilotinib vs dasatinib have been published (Rogers e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::18b8aa7be0438a97e28f7d7cedb0da05
https://doi.org/10.1182/blood.v126.23.2090.2090
https://doi.org/10.1182/blood.v126.23.2090.2090
Autor:
Hongbo Yang, Anuja Roy, Chelsey Yang, Evangeline McDonald, Arun Krishna, Emil T Kuriakose, Denise Globe, David Siegel, Sundar Jagannath
Publikováno v:
Blood. 126:5369-5369
Background: Almost all patients with multiple myeloma will eventually become relapsed/refractory (RRMM). Current treatments for RRMM are mainly targeted therapies, composed of dual and triple agents including proteasome inhibitors (PIs) with dexameth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::80e9ba05ace46d00143b2c4269018ad0
https://doi.org/10.1182/blood.v126.23.5369.5369
https://doi.org/10.1182/blood.v126.23.5369.5369
Publikováno v:
Blood. 124:5992-5992
Background: FMS-like tyrosine kinase-3 (FLT3) mutation is present in approximately one-third of AML patients. Internal tandem duplication mutations of FLT3 (FLT3-ITD) mutation in AML have been associated with poorer prognosis compared to FLT3 wild ty
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0196f542de26d59dc26a402a22514e41
https://doi.org/10.1182/blood.v124.21.5992.5992
https://doi.org/10.1182/blood.v124.21.5992.5992